"Another comment- Could get to break even without another raise."
Garland said it.
Unlike Medicare, VA can negotiate drug prices, so I wonder where they settled on Andexxa. Adding it to the VA formulary is a significant step and it will trigger another jump up in revenue and revenue estimates. With three sets of ongoing partnering talks, B, C and Europe A, I would expect some kind of deal by year end.
The last go-around with FDA on Andexxa pretty much signaled that urgent surgery trial will have a control arm. Lots of momentum headed in the right direction. This is setting up for a good quarterly call.